logo-loader

Sidus Space granted National Oceanographic and Atmosphere Administration (NOAA) Tier 1 license for upcoming LizzieSat-1 mission

Published: 10:09 29 Nov 2022 EST

Sidus Space Inc - planet earth from space

Sidus Space Inc (NASDAQ:SIDU) said it has secured US regulatory approval to provide global data services from its upcoming LizzieSat-1 mission through a Tier 1 license granted by the National Oceanographic and Atmosphere Administration (NOAA).

“Securing the NOAA Tier 1 license, which has the fewest conditions under a streamlined regulatory regime that came into effect in 2020, is an important milestone toward our readiness to launch,” commented Sidus Space CEO Carol Craig.

“We look forward to sharing additional milestone achievements as we continue to execute our planned development and preparations for our LizzieSat constellation,” she continued.

READ: Sidus Space partners with Capital C on maritime satellite design and surveillance systems

LizzieSat-1, the maiden flight of the planned LizzieSat satellite constellation, is expected to launch on a SpaceX Falcon 9 in 2023 from Cape Canaveral, Florida, into a low earth orbit.

Sidus said this orbit, matched with LizzieSat’s precise attitude control capabilities, will allow for the collection of thousands of earth images daily during LizzieSat-1’s multi-year mission.

Data from the mission will be supplied to clients and consumers focused on maritime shipping industry activities, climate change, and other commercially relevant interests, the company added.

Sidus Space, located in Cape Canaveral, Florida, operates from a 35,000-square-foot manufacturing, assembly, integration, and testing facility focused on commercial satellite design, manufacture, launch, and data collection. 

Contact the author at emily.jarvie@proactiveinvestors.com

Follow her on Twitter @emilyjjarvie

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

2 hours, 28 minutes ago